|
|
|
|
|
|
by tptacek
2776 days ago
|
|
|
It's not "inexplicable". uniQure is a going concern with treatments in the pipeline for Huntingtons, hemophilia, and congestive heart failure. They have a finite amount of resources and are allocating them to projects that they're more optimistic about than this one. Glybera is of questionable efficacy and is very expensive to administer (they're on the hook for long-term monitoring for everyone they dose). It's not at all hard to see why they'd stop production. |
|
|